The global Glipizide market is expected to reach USD 1.5 billion by 2030.
Glipizide tablets are the most commonly used form of the drug and accounted for over 50% of the total revenue in 2017. The sustained release tablets segment is expected to grow at a CAGR of 6% during the forecast period owing to their prolonged action and reduced side effects as compared with other formulations such as tablets or injections.
North America dominated the global Glipizide market in 2017 with over 40% share due to high prevalence rates among diabetic patients and increasing awareness about diabetes among people in this region. Europe followed North America with over 30% share owing to increasing prevalence rates among diabetic patients and growing awareness about diabetes among people in this region. Asia Pacific was third largest regional contributor accounting for nearly 25%.
Some Of The Growth Factors Of This Market:
- Glipizide is a drug that is used to treat type 2 diabetes.
- It is a sulfonylurea drug, which works by increasing the amount of insulin released from the pancreas and by decreasing the amount of sugar produced in the liver.
- It was first marketed in 1981 and has been available as a generic since 2003.
- The patent for Glipizide expired in 2006, so it can be manufactured by any company without paying royalties to Novo Nordisk A/S, who originally developed it and still owns some patents on it for other uses such as treatment of obesity or high blood pressure.
- Glipizide has been shown to be effective at lowering blood glucose levels in people with type 2 diabetes mellitus.
Industry Growth Insights published a new data on “Glipizide (CAS 29094-61-9) Market”. The research report is titled “Glipizide (CAS 29094-61-9) Market research by Types (Glipizide Tablets, Glipizide Sustained Release Tablets, Others), By Applications (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Players/Companies Pfizer, United Laboratories, Disha Pharma, PIDI, Lukang Pharma, Jingfeng Zhiyao, Jumpcan, CCPC, Yashica Pharma, Apotex, TEVA”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Glipizide (CAS 29094-61-9) Market Research Report
By Type
Glipizide Tablets, Glipizide Sustained Release Tablets, Others
By Application
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
By Companies
Pfizer, United Laboratories, Disha Pharma, PIDI, Lukang Pharma, Jingfeng Zhiyao, Jumpcan, CCPC, Yashica Pharma, Apotex, TEVA
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
235
Number of Tables & Figures
165
Customization Available
Yes, the report can be customized as per your need.
 Industry Outlook.svg)
Global Glipizide (CAS 29094-61-9) Market Report Segments:
The global Glipizide (CAS 29094-61-9) market is segmented on the basis of:
Types
Glipizide Tablets, Glipizide Sustained Release Tablets, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- United Laboratories
- Disha Pharma
- PIDI
- Lukang Pharma
- Jingfeng Zhiyao
- Jumpcan
- CCPC
- Yashica Pharma
- Apotex
- TEVA
 Market Overview.svg)
Highlights of The Glipizide (CAS 29094-61-9) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Glipizide Tablets
- Glipizide Sustained Release Tablets
- Others
- By Application:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Glipizide (CAS 29094-61-9) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Glipizide is a medication used to treat type 2 diabetes. It works by helping the body to control blood sugar levels. Glipizide is usually taken once a day with food.
Some of the major companies in the glipizide (cas 29094-61-9) market are Pfizer, United Laboratories, Disha Pharma, PIDI, Lukang Pharma, Jingfeng Zhiyao, Jumpcan, CCPC, Yashica Pharma, Apotex, TEVA.
The glipizide (cas 29094-61-9) market is expected to register a CAGR of 6%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Glipizide (CAS 29094-61-9) Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Glipizide (CAS 29094-61-9) Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Glipizide (CAS 29094-61-9) Market - Supply Chain
4.5. Global Glipizide (CAS 29094-61-9) Market Forecast
4.5.1. Glipizide (CAS 29094-61-9) Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Glipizide (CAS 29094-61-9) Market Size (000 Units) and Y-o-Y Growth
4.5.3. Glipizide (CAS 29094-61-9) Market Absolute $ Opportunity
5. Global Glipizide (CAS 29094-61-9) Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Glipizide (CAS 29094-61-9) Market Size and Volume Forecast by Type
5.3.1. Glipizide Tablets
5.3.2. Glipizide Sustained Release Tablets
5.3.3. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Glipizide (CAS 29094-61-9) Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Glipizide (CAS 29094-61-9) Market Size and Volume Forecast by Application
6.3.1. Hospital Pharmacies
6.3.2. Retail Pharmacies
6.3.3. Online Pharmacies
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Glipizide (CAS 29094-61-9) Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Glipizide (CAS 29094-61-9) Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Glipizide (CAS 29094-61-9) Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Glipizide (CAS 29094-61-9) Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Glipizide (CAS 29094-61-9) Demand Share Forecast, 2019-2026
9. North America Glipizide (CAS 29094-61-9) Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Glipizide (CAS 29094-61-9) Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Glipizide (CAS 29094-61-9) Market Size and Volume Forecast by Application
9.4.1. Hospital Pharmacies
9.4.2. Retail Pharmacies
9.4.3. Online Pharmacies
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Glipizide (CAS 29094-61-9) Market Size and Volume Forecast by Type
9.7.1. Glipizide Tablets
9.7.2. Glipizide Sustained Release Tablets
9.7.3. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Glipizide (CAS 29094-61-9) Demand Share Forecast, 2019-2026
10. Latin America Glipizide (CAS 29094-61-9) Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Glipizide (CAS 29094-61-9) Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Glipizide (CAS 29094-61-9) Market Size and Volume Forecast by Application
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Pharmacies
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Glipizide (CAS 29094-61-9) Market Size and Volume Forecast by Type
10.7.1. Glipizide Tablets
10.7.2. Glipizide Sustained Release Tablets
10.7.3. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Glipizide (CAS 29094-61-9) Demand Share Forecast, 2019-2026
11. Europe Glipizide (CAS 29094-61-9) Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Glipizide (CAS 29094-61-9) Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Glipizide (CAS 29094-61-9) Market Size and Volume Forecast by Application
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Glipizide (CAS 29094-61-9) Market Size and Volume Forecast by Type
11.7.1. Glipizide Tablets
11.7.2. Glipizide Sustained Release Tablets
11.7.3. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Glipizide (CAS 29094-61-9) Demand Share, 2019-2026
12. Asia Pacific Glipizide (CAS 29094-61-9) Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Glipizide (CAS 29094-61-9) Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Glipizide (CAS 29094-61-9) Market Size and Volume Forecast by Application
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Glipizide (CAS 29094-61-9) Market Size and Volume Forecast by Type
12.7.1. Glipizide Tablets
12.7.2. Glipizide Sustained Release Tablets
12.7.3. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Glipizide (CAS 29094-61-9) Demand Share, 2019-2026
13. Middle East & Africa Glipizide (CAS 29094-61-9) Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Glipizide (CAS 29094-61-9) Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Glipizide (CAS 29094-61-9) Market Size and Volume Forecast by Application
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Glipizide (CAS 29094-61-9) Market Size and Volume Forecast by Type
13.7.1. Glipizide Tablets
13.7.2. Glipizide Sustained Release Tablets
13.7.3. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Glipizide (CAS 29094-61-9) Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Glipizide (CAS 29094-61-9) Market: Market Share Analysis
14.2. Glipizide (CAS 29094-61-9) Distributors and Customers
14.3. Glipizide (CAS 29094-61-9) Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Pfizer
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. United Laboratories
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Disha Pharma
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. PIDI
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Lukang Pharma
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Jingfeng Zhiyao
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Jumpcan
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. CCPC
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Yashica Pharma
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Apotex
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. TEVA
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
